Skip to main content
Erschienen in: Current Geriatrics Reports 2/2023

07.02.2023 | Review

Neuromodulation in the Older Woman: An Advanced Treatment Option for Urgency Urinary Incontinence

verfasst von: Michele O’Shea, Cindy L Amundsen

Erschienen in: Current Geriatrics Reports | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Urgency urinary incontinence (UUI) disproportionately impacts older women, and treatment strategies should minimize known harms while optimizing benefits. In the present review, we seek to provide an overview of the recent literature as it relates to neuromodulation and the treatment of older women with UUI. We also highlight recent innovations to neuromodulation therapy which have the potential to significantly improve access to neuromodulation for older women, in addition to improvements in longevity and cost-effectiveness.

Recent Findings

With respect to sacral neuromodulation (SNM) in older women, a randomized trial of women with non-neurogenic UUI found that older women undergoing SNM did not experience differential incontinence outcomes compared with younger women. In a separate retrospective cohort study, higher decade of age was found to be associated with lower odds of implantation and higher addition of therapies post-implantation. The development of a new MRI-compatible SNM lead has increased the number of eligible patients for SNM and the increased longevity of the new pulse generator will decrease the need for repeat surgery for generator replacements. With respect to posterior tibial nerve stimulation (PTNS), a significant barrier to access is currently the requirement for in-office visits for treatment. Newer implantable posterior tibial nerve electrodes have shown promising short-term efficacy and would provide a way for home-based remote PTNS obviating previous transportation-based barriers.
Literatur
1.
Zurück zum Zitat Abufaraj M, Xu T, Cao C, Siyam A, Isleem U, Massad A et al. Prevalence and trends in urinary incontinence among women in the United States, 2005–2018. Am J Obstet Gynecol. 2021 Aug;225(2):166.e1-166.e12. Abufaraj M, Xu T, Cao C, Siyam A, Isleem U, Massad A et al. Prevalence and trends in urinary incontinence among women in the United States, 2005–2018. Am J Obstet Gynecol. 2021 Aug;225(2):166.e1-166.e12.
2.
Zurück zum Zitat Hung KJ, Awtrey CS, Tsai AC. Urinary incontinence, depression, and economic outcomes in a cohort of women between the ages of 54 and 65 years. Obstet Gynecol. 2014 Apr;123(4):822–7. Hung KJ, Awtrey CS, Tsai AC. Urinary incontinence, depression, and economic outcomes in a cohort of women between the ages of 54 and 65 years. Obstet Gynecol. 2014 Apr;123(4):822–7.
3.
Zurück zum Zitat Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006 Sep;54(9):1325–33. Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006 Sep;54(9):1325–33.
4.
Zurück zum Zitat Xu D, Kane RL. Effect of urinary incontinence on older nursing home residents’ self-reported quality of life. J Am Geriatr Soc. 2013 Sep;61(9):1473–81. Xu D, Kane RL. Effect of urinary incontinence on older nursing home residents’ self-reported quality of life. J Am Geriatr Soc. 2013 Sep;61(9):1473–81.
5.
Zurück zum Zitat Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014 Jan;65(1):79–95. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014 Jan;65(1):79–95.
6.
Zurück zum Zitat Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997 Sep;26(5):367–74. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997 Sep;26(5):367–74.
7.
Zurück zum Zitat Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558–63. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558–63.
8.
Zurück zum Zitat Dengler KL, High RA, Moga DC, Zillioux J, Wagg A, DuBeau CE et al. Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. Urogynecology (Hagerstown). 2023 Jan 1;29(1S Suppl 1):S1–19. Dengler KL, High RA, Moga DC, Zillioux J, Wagg A, DuBeau CE et al. Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. Urogynecology (Hagerstown). 2023 Jan 1;29(1S Suppl 1):S1–19.
9.
Zurück zum Zitat Sanses TVD, Zillioux J, High RA, Dengler KL, Ackenbom MF, DuBeau CE et al. Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. Urogynecology (Hagerstown). 2023 Jan 1;29(1S Suppl 1):S20–39. Sanses TVD, Zillioux J, High RA, Dengler KL, Ackenbom MF, DuBeau CE et al. Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. Urogynecology (Hagerstown). 2023 Jan 1;29(1S Suppl 1):S20–39.
10.
Zurück zum Zitat Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar;175(3):401–7. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar;175(3):401–7.
11.
Zurück zum Zitat De Wachter S, Vaganee D, Kessler TM. Sacral Neuromodulation: Mechanism of Action.Eur Urol Focus. 2020 Sep15;6(5):823–5. De Wachter S, Vaganee D, Kessler TM. Sacral Neuromodulation: Mechanism of Action.Eur Urol Focus. 2020 Sep15;6(5):823–5.
12.
Zurück zum Zitat Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during Sacral Neuromodulation for overactive bladder. J Urol. 2017 Dec;198(6):1379–85. Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during Sacral Neuromodulation for overactive bladder. J Urol. 2017 Dec;198(6):1379–85.
13.
Zurück zum Zitat Wenzler DL, Burks FN, Cooney M, Peters KM. Proof of concept trial on changes in current perception threshold after sacral neuromodulation. Neuromodulation. 2015 Apr;18(3):228–31. discussion 232. Wenzler DL, Burks FN, Cooney M, Peters KM. Proof of concept trial on changes in current perception threshold after sacral neuromodulation. Neuromodulation. 2015 Apr;18(3):228–31. discussion 232.
14.
Zurück zum Zitat Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ. Urologic Diseases in America Project. Outcomes of Sacral Neuromodulation in a privately insured Population. Neuromodulation. 2016 Oct;19(7):780–4. Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ. Urologic Diseases in America Project. Outcomes of Sacral Neuromodulation in a privately insured Population. Neuromodulation. 2016 Oct;19(7):780–4.
15.
Zurück zum Zitat Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial. Eur Urol. 2018 Jul;74(1):66–73. Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial. Eur Urol. 2018 Jul;74(1):66–73.
16.
Zurück zum Zitat Komesu YM, Amundsen CL, Richter HE, Erickson SW, Ackenbom MF, Andy UU et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018 Jan;218(1):111.e1-111.e9. Komesu YM, Amundsen CL, Richter HE, Erickson SW, Ackenbom MF, Andy UU et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018 Jan;218(1):111.e1-111.e9.
17.
Zurück zum Zitat High RA, Winkelman W, Panza J, Sanderson DJ, Yuen H, Halder G et al. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?Int Urogynecol J. 2021Jan;32(1):149–57. High RA, Winkelman W, Panza J, Sanderson DJ, Yuen H, Halder G et al. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?Int Urogynecol J. 2021Jan;32(1):149–57.
18.
Zurück zum Zitat Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, et al. Cost-effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory urgency urinary incontinence: results of the ROSETTA Randomized Trial. J Urol. 2020 May;203(5):969–77. Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, et al. Cost-effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory urgency urinary incontinence: results of the ROSETTA Randomized Trial. J Urol. 2020 May;203(5):969–77.
19.
Zurück zum Zitat Huang X, Jiang GJ. Magnetic resonance imaging interactions with a sacral neuromodulation system. Neurourol Urodyn. 2021 Nov;40(8):1862–8. Huang X, Jiang GJ. Magnetic resonance imaging interactions with a sacral neuromodulation system. Neurourol Urodyn. 2021 Nov;40(8):1862–8.
20.
Zurück zum Zitat Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Jairam R, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn. 2018 Feb;37(S2):9–16. Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Jairam R, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn. 2018 Feb;37(S2):9–16.
21.
Zurück zum Zitat Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Perrouin-Verbe MA, et al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. Neurourol Urodyn. 2020 Apr;39(4):1108–14. Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Perrouin-Verbe MA, et al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. Neurourol Urodyn. 2020 Apr;39(4):1108–14.
22.
Zurück zum Zitat Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010 Apr;183(4):1438–43. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010 Apr;183(4):1438–43.
23.
Zurück zum Zitat Gordon T, Merchant M, Ramm O, Patel M. Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome. Female Pelvic Med Reconstr Surg. 2021 Jul 1;27(7):444–9. Gordon T, Merchant M, Ramm O, Patel M. Factors Associated With Long-Term Use of Percutaneous Tibial Nerve Stimulation for Management of Overactive Bladder Syndrome. Female Pelvic Med Reconstr Surg. 2021 Jul 1;27(7):444–9.
24.
Zurück zum Zitat Salatzki J, Liechti MD, Spanudakis E, Gonzales G, Baldwin J, Haslam C, et al. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. BJU Int. 2019 May;123(5A):E20–8. Salatzki J, Liechti MD, Spanudakis E, Gonzales G, Baldwin J, Haslam C, et al. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. BJU Int. 2019 May;123(5A):E20–8.
25.
Zurück zum Zitat Kapriniotis K, Jenks J, Toia B, Pakzad M, Gresty H, Stephens R et al. Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation? Neurourol Urodyn. 2022 Jun;41(5):1172–6. Kapriniotis K, Jenks J, Toia B, Pakzad M, Gresty H, Stephens R et al. Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation? Neurourol Urodyn. 2022 Jun;41(5):1172–6.
26.
Zurück zum Zitat Yang DY, Zhao LN, Qiu MX. Treatment for overactive bladder: A meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation. Medicine (Baltimore). 2021 May 21;100(20):e25941. Yang DY, Zhao LN, Qiu MX. Treatment for overactive bladder: A meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation. Medicine (Baltimore). 2021 May 21;100(20):e25941.
27.
Zurück zum Zitat Schreiner L, Nygaard CC, Dos Santos TG, Knorst MR, da Silva Filho IG. Transcutaneous tibial nerve stimulation to treat urgency urinary incontinence in older women: 12-month follow-up of a randomized controlled trial. Int Urogynecol J. 2021 Mar;32(3):687–93. Schreiner L, Nygaard CC, Dos Santos TG, Knorst MR, da Silva Filho IG. Transcutaneous tibial nerve stimulation to treat urgency urinary incontinence in older women: 12-month follow-up of a randomized controlled trial. Int Urogynecol J. 2021 Mar;32(3):687–93.
28.
Zurück zum Zitat Heesakkers JPFA, Digesu GA, van Breda J, Van Kerrebroeck P, Elneil S. A novel leadless, miniature implantable tibial nerve Neuromodulation System for the management of overactive bladder complaints. Neurourol Urodyn. 2018 Mar;37(3):1060–7. Heesakkers JPFA, Digesu GA, van Breda J, Van Kerrebroeck P, Elneil S. A novel leadless, miniature implantable tibial nerve Neuromodulation System for the management of overactive bladder complaints. Neurourol Urodyn. 2018 Mar;37(3):1060–7.
29.
Zurück zum Zitat Amundsen C, Toozs-Hobson P, Benson K, Digesu A, Lane F, Ferrante K, Pezzella A. OASIS Pivotal Trial to Evaluate the Safety and Efficacy of the RENOVA iStim System™ for the Treatment of Women with OAB. In Austin, TX; 2022. Amundsen C, Toozs-Hobson P, Benson K, Digesu A, Lane F, Ferrante K, Pezzella A. OASIS Pivotal Trial to Evaluate the Safety and Efficacy of the RENOVA iStim System for the Treatment of Women with OAB. In Austin, TX; 2022.
30.
Zurück zum Zitat Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S et al. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 May 1;28(5):287–92. Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S et al. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 May 1;28(5):287–92.
31.
Zurück zum Zitat Groen J, Amiel C, Bosch JLHR. Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator. Neurourol Urodyn. 2005;24(3):226–30.CrossRefPubMed Groen J, Amiel C, Bosch JLHR. Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator. Neurourol Urodyn. 2005;24(3):226–30.CrossRefPubMed
32.
Zurück zum Zitat Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn. 2005;24(7):643–7.CrossRefPubMed Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn. 2005;24(7):643–7.CrossRefPubMed
33.
Zurück zum Zitat Goldman HB, Amundsen CL, Mangel J, Grill J, Bennett M, Gustafson KJ, et al. Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. Neurourol Urodyn. 2008;27(6):499–503.CrossRefPubMedPubMedCentral Goldman HB, Amundsen CL, Mangel J, Grill J, Bennett M, Gustafson KJ, et al. Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. Neurourol Urodyn. 2008;27(6):499–503.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat van Breda HMK, Farag FF, Martens FMJ, Heesakkers JPFA, Rijkhoff NJM, Subject-Controlled. On-demand, dorsal genital nerve stimulation to treat urgency urinary incontinence; a pilot. Front Neurosci. 2016;10:24.PubMedPubMedCentral van Breda HMK, Farag FF, Martens FMJ, Heesakkers JPFA, Rijkhoff NJM, Subject-Controlled. On-demand, dorsal genital nerve stimulation to treat urgency urinary incontinence; a pilot. Front Neurosci. 2016;10:24.PubMedPubMedCentral
35.
Zurück zum Zitat Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010 Mar;251(3):441–9. Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010 Mar;251(3):441–9.
Metadaten
Titel
Neuromodulation in the Older Woman: An Advanced Treatment Option for Urgency Urinary Incontinence
verfasst von
Michele O’Shea
Cindy L Amundsen
Publikationsdatum
07.02.2023
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 2/2023
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-023-00379-3

Weitere Artikel der Ausgabe 2/2023

Current Geriatrics Reports 2/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.